January 27, 2021 (Viz Release) – – Global Trac Solutions (Stock Symbol: PSYC) Enters Joint Partnership with Minerco, Inc ( Stock Symbol: MINE)
– Long Established Expertise in the Administration of Business Payments and Operations.
– New Commitment for Entry into the Lucrative Psychedelic Medicinal Field.
– Formation of New Advisory Board with Three Distinguished Members.
– MOU Signed with Digital Mental Health Startup for JV Partnership.
– New Digital Platform for Psychedelic Spotlight Web Magazine.
Global Trac Solutions (OTC: PSYC) is a diversified holding company dedicated to identifying new and emerging industries. By utilizing years of business development expertise, the PSYC team of innovators continuously leverages experience to effectively execute go-to-market strategies in order to position for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
PSYC a digital media leader within the emerging sector of medicinal psychedelics, is pleased to announce that the Company has entered into a Joint Venture Partnership (the “JV”) with Minerco, Inc. (OTC: MINE) (“MINE”), a Jamaican-based company specializing in growing, research, production and distribution of psilocybin mushrooms and marketing worldwide.
The JV creates an opportunity for the companies to collaborate on the co-development and hosting of virtual conferences and forums focused on educating, informing, and showcasing the potential medicinal benefits of psilocybin mushrooms, including the psilocybin-based products MINE is developing. Additionally, the JV allows for PSYC to serve as one of the primary digital marketing partners for MINE as they move forward with their focus of bringing their products to market.
“We are extremely delighted to partner with MINE, a company that is deeply-rooted in the sector of psilocybin mushrooms,” said Global Trac Solutions, Inc. CEO, David Flores. “And we’re thrilled to be able to combine our collective resources to develop and produce virtual conferences and forums in the coming months that we believe will effectively highlight this exciting sector within the psychedelic industry.”
Since 2017, PSYC has been a pioneer in the emerging software and payment processing sector of the cannabis industry and has established itself as a trusted resource for businesses operating within the industry. Most recently, PSYC has expressed its intent and commitment to positioning itself at the forefront of the psychedelic revolution and as a resource center for discovering and understanding the latest research and business opportunities surrounding psychedelic inspired medicines. In conjunction with the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, investors are speculating that the psychedelic boom could be bigger than that of cannabis.
– PSYC Announces Formation of Advisory Board with Three Leading Voices from the Medical, Science, and Psychotherapeutic Sectors
On January 5th PSYC announced the formation of the Company’s Advisory Board. Joining its newly established board is George Y. Salameh, MD, Hyder A. Khoja, PhD, and Kelli Foulkroud, MS, LPA, LPC, RYT. And as PSYC moves ahead with its growth within the emerging sectors of medicinal psychedelics and digital mental health, these advisors bring tremendous value to the Company through their collective knowledge and expertise.
Dr. Salameh brings more than 35 years of experience within the medical community where he has served in the sectors of family and emergency practice and has held his California State Medical License since 1987. In addition to his extensive knowledge and experience as a physician, Dr. Salameh has also achieved success as an entrepreneur and as a real estate developer. He has also provided strategic consulting services for startup biotech and medical product companies in collaboration with San Diego venture capitalists for the past ten years.
Dr. Khoja has over 19 years of experience in the fields of molecular biology and genetic engineering and is an expert in translating ideas into action, including innovation, commercialization, and knowledge mobilization. His expertise in science and policy domains has led to a distinguished career in scientific research and business development with a passion for Molecular Biology and Genetic Engineering. Dr. Khoja leverages his knowledge in drug discoveries from plant extracts and analytics to validate consistent medical-grade plant nano-molecules for therapeutics. Dr. Khoja received his doctorate (Ph.D.), in 2003 with honors in Molecular Biology and Genetic Engineering from a French Ivy league: INP-ENSAT and had his Post-doctoral training from the Michigan State University a US land grant university.
Kelli Foulkrod, MS, LPA, LPC, RYT has worked in the mental health field for over 19 years in a variety of academic and clinical settings. She is a transpersonal psychotherapist, trauma-informed yoga teacher, ceremonialist, and psychedelic integration therapist based in Austin, Texas, and is also licensed in Colorado. For the past ten years, she has managed her private practice, the Organic Mental Health Center, where she has focused her expertise and energy in supporting healing in trauma and complex PTSD, pregnant and postpartum women and their families, reproductive trauma, grief and loss, psychosis, bipolar, OCD, and treatment resistant depression.
Over the coming months, it is the intent of PSYC management to strategically add additional experts to its Advisory Board whom it believes may contribute to its continued growth and emergence as a leader within the sectors of medicinal psychedelics and digital mental health.
– MOU with Digital Mental Health Startup, PsycheDev Inc. to Co-Develop Digital Mental Health Platform Through JV Partnership
On December 29th PSYC announce it has entered into a Memorandum of Understanding (“MOU”) with PsycheDev Inc. (“PsycheDev”), a Canadian based start-up company focused on the development and deployment of technology-driven mental wellness-enhancing solutions.
In effect, the execution of the MOU outlines the general terms to be applied by each of the respective companies in entering into advanced discussions surrounding the intended establishment of a Joint Venture Partnership Agreement (the “JV”) which will focus on the effective co-development and launch of the PsycheDev platform and app. Furthermore, it is the intent of PSYC, via the anticipated execution of a JV, to acquire an equity stake in PsycheDev through a capital investment and to work alongside the company’s Founder and CEO, Justin Roy, to bring their cutting-edge digital mental health platform to market during the latter quarters of 2021.
– Leading Psychedelic Media Site Launches New Digital Platform
On December 23rd PSYC announced the launch of a new web platform for its Psychedelic Spotlight web magazine. The new site is part of the continued growth Psychedelic Spotlight is experiencing. In Q4 of 2020 a record number of new users visited this site.
The new PSYC site will present a sleeker and more appealing visual experience. Some of the most important and beneficial updates have also been infused on the backend. This new site has been developed with SEO and Google ranking analytics in mind in order to more effectively position it to capture as much of the growing audience within this sector as possible.
PSYC through its digital media marketing partner, SunCity Advising, expects to rollout additional pages and features for the Psychedelic Spotlight website in its ongoing mission of delivering the most resourceful and content-rich web platform in the sector of medicinal psychedelics.
For more information on Global Trac Solutions (PSYC) visit https://www.globaltracsolutions.com
DISCLOSURE: CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CA is NOT affiliated in any manner with any company mentioned herein. CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CA has been compensated $400.00 for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.